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The question of which of the CYP 
enzymes are responsible for formation of 
AAIa remains still to be investigated. The 
in vitro experiments of Xiao et al.1 indicate 
that CYP1A generates AAIa. However, 
the model used to evaluate CYP1A par-
ticipation in formation of AAIa in vivo, 
mice treated with an inducer of CYP1A 
3-methycholanthrene (MC), did not bring 
unambiguous results. Namely, MC also 
induces other enzymes besides CYP1A. 
Although treatment of mice with MC 
leads to a decrease in AAI concentrations 
in the liver and kidney, an increase in 
AAIa concentrations was found not in the 
liver but only in the kidney of mice treated 
with the higher dose of AAI (20 mg/kg). 
An increase in excretion of AAIa due to 
its conjugation with glucuronide, caused 
by induction of UDP-glucuronosyltrans-
ferase with MC, could occur. Nevertheless, 
because CYP1A enzymes also activate 
AAI to species forming DNA adducts,6 the 
decrease of AAI in liver and kidney might 
also result from this reaction. Moreover, 
NQO1, which is also eﬃciently induced 
by MC, could contribute to decreased AAI 
levels in MC-treated mice.
Taking into account all data known 
at the present time, we propose that the 
pathways of AAI metabolism are dictated 
by the binding aﬃnity of AAI to CYP1A 
or NQO1, and their enzymatic turnover, 
as well as by the balance of the eﬃciency 
of CYP1A at oxidizing versus reducing 
AAI. In order to conﬁrm this assumption 
and to complement the work of Xiao et 
al.,1 we have started a study investigat-
ing formation of AAI-DNA adducts in 
the HRN mouse model and in models in 
which CYP1A genes are deleted.
Although the impact of individual 
enzymes that metabolize AAI on its 
nephrotoxicity and carcinogenicity in vivo 
is still not entirely resolved, one question 
was unambiguously answered by Xiao et 
al.:1 hepatic CYP enzymes detoxicate AAI 
in mice, thus decreasing its renal toxicity. 
The evaluation of interindividual vari-
ations in the human enzymes playing a 
major role in AAI activation and detoxi-
cation, including their genetic polymor-
phisms, remains a major challenge to 
explain an individual’s susceptibility to 
AAI and to predict cancer risk among 
AAN and BEN patients.
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Plasma exchange for myeloma 
kidney: cast(s) away?
WF Clark1 and AX Garg1,2
Leung et al. (this issue) present a retrospective study of 40 patients. 
Observations in 14/40 led to the suggestion of restitution of plasma 
exchange for light-chain responsive, biopsy-proven myeloma kidney 
until a better randomized control trial (RCT) is constructed. A careful 
analysis of their study and a recent RCT suggest little difference in 
outcome between plasma exchange and control groups. The analysis 
supports restitution of a better RCT of plasma exchange for myeloma 
kidney rather than off-label use.  
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Acute kidney injury in the setting of mul-
tiple myeloma has a strong impact on 
patient morbidity, mortality, health-care 
utilization, and cost.1–4 A unique and 
important cause of acute kidney injury 
in multiple myeloma is cast nephropathy, 
in which renal inﬂammation results from 
an excess of filtered monoclonal light 
chains that are transported to the inter-
stitium of the kidney via speciﬁc recep-
tors in the proximal tubule. The receptors 
become overloaded by the light chains, 
which then combine with Tamm-Horsfall 
protein, forming obstructive casts in the 
renal tubules.5 Plasma exchange has been 
shown to remove light chains transiently 
and may have an adjunctive eﬀect when 
combined with eﬀective chemotherapy 
in the treatment of cast nephropathy.3,6,7 
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Two small randomized controlled trials 
(RCTs) of 29 and 21 patients provided 
conﬂicting results regarding the beneﬁt of 
plasma exchange.8,9 Recently, in a larger 
RCT, 97 patients presenting with myeloma 
and acute renal failure were randomized 
to receive standard chemotherapy with 
or without plasma exchange. This study 
failed to demonstrate a beneﬁt of the addi-
tion of plasma exchange therapy.10 Leung 
et al.11 (this issue) now reconsider the 
role of plasma exchange in myeloma cast 
nephropathy in a retrospective case series. 
The series suﬀers from the usual short-
comings of a small retrospective analysis 
of a heterogeneous mixture of acute, sub-
acute, and chronic renal failure patients 
with the diagnosis of myeloma (incident 
and recurrent cases) who receive a range 
of 1–19 plasma exchanges and 12 diﬀerent 
chemotherapy protocols.
In this report, 40 cases are initially 
reported; 28 of these patients agreed to 
undergo renal biopsy, of whom 18 had 
cast nephropathy as a diagnosis. Of the 
18, 14 had serum free-light chain meas-
urement, and of these, 50% demonstrated 
a renal response to their plasma exchange 
therapy plus or minus other types of 
chemotherapy. In an exploratory uncor-
rected sub-sub-sub-subgroup analysis, 
nine patients had a greater than 50% 
reduction in serum free-light chains with 
a diagnosis of cast nephropathy, and seven 
demonstrated a renal response. A renal 
response was a composite outcome, which 
required the patient to be alive at 6 months 
and to have had a reduction in his or her 
baseline serum creatinine of 50% and to 
be independent of dialysis. Leung et al.11 
contend that their results are dependent 
on identiﬁcation of patients with myeloma 
and renal failure who have cast nephropa-
thy conﬁrmed by renal biopsy and have 
serum free-light chain measurement. 
Unfortunately, only 14 of their 40 subjects 
met these requirements. This retrospective 
analysis noted no correlation between the 
number of plasma exchanges that patients 
received and their serum free-light chain 
response or their renal response. Although 
the subjects did receive 12 diﬀerent types 
of chemotherapy, renal response did show 
a weak correlation with high-dose dexa-
methasone therapy. The renal response 
rates in the 18 patients with biopsy-proven 
cast nephropathy and the 14 patients with 
biopsy-proven cast nephropathy and 
serum free-light chain measurement are 
similar to the response rates noted for both 
control and plasma exchange subjects in 
the previous RCT (Table 1). The subjects in 
the previous RCT had incident myeloma, 
were followed prospectively, and had well-
deﬁned acute renal failure.10 The expected 
incidence of cast nephropathy for this well-
deﬁned group would be anywhere between 
77% and 100%.1,2,4 Leung et al.11 used a 
composite outcome that required that the 
patient be alive, have a 50% reduction in 
baseline serum creatinine, and dialysis 
independence at 6 months. The Clark et 
al.10 outcome was death, dialysis depend-
ence, or creatinine clearance less than 
30 ml/min/1.73 m2, and the inverse would 
be similar to the Leung et al.11 outcome: 
life, dialysis independence, and serum cre-
atinine improvement of 50% at 6 months 
from the time of diagnosis of acute renal 
failure (Table 1).
Table 1 demonstrates the comparative 
outcomes and shows that Leung et al.’s11 
plasma exchange group did not have a sig-
niﬁcantly diﬀerent outcome from that of 
the control and plasma exchange arms of 
the Clark et al. RCT10 (Table 1). However, 
the optimal outcomes noted for the sub-
subgroup of cast nephropathy patients 
who responded with a 50% reduction in 
serum free-light chains after an unspeci-
ﬁed number of plasma exchanges and dif-
fering chemotherapy appear superior to 
the RCT results. It is the outcome of this 
highly selected subgroup that has encour-
aged Leung et al.11 to suggest restitution 
of plasma exchange therapy.
The increased beneﬁt for the optimized 
patient group with biopsy and serum free-
light chain reduction of 50% is more likely 
to be due to the type of chemotherapy and 
the responsiveness of the myeloma, rather 
than the plasma exchange therapy.2,6,7 This 
is why the mortality rate among patients 
who received standardized chemotherapy 
in the Clark et al. study10 did not diﬀer 
between the plasma exchange and con-
trol arms, in contrast to the major dif-
ference between the response and the 
non-response group in the Leung et al. 
study.11 The magnitude of survival advan-
tage reported by Leung et al.11 would be 
expected if a 50% reduction in serum free-
light chain levels was merely a marker for 
patients whose myeloma was responsive 
to chemotherapy. Plasma exchange is 
not able to induce a lasting light chain 
response in the absence of chemotherapy 
in patients with myeloma.6,7 The weak 
correlation noted by Leung et al.11 for 
renal response to chemotherapy, coupled 
with the lack of association of the number 
of plasma exchanges with serum free-light 
chain response, is consistent with this 
interpretation.
Plasma exchange without chemo-
therapy is unlikely to exhibit clinical 
benefit in cast nephropathy because 
of free-light chain removal. Free-light 
chains are relatively small molecules 
(25–50 kilodaltons) and are present in 
similar concentration in the intravas-
cular and extravascular compartments.6 
Thus about 15%–20% of free-light chains 
are available for removal, of which one 
volume plasma exchange would remove 
about 10%–15%. This would have lit-
tle impact if chemotherapy did not 
reduce production. This has been clearly 
Table 1 | Outcomes
Outcomes: 
6 months
Composite renal response Dialysis independence
Leung et al.11 18/40 = 45%
Myeloma, renal failure
2/9 = 22%
PE
 9/18 = 50%
PE, CN
 
 7/14 = 50%
PE, CN, sFLC
 
Clark et al.10 13/26 = 50%
Control
7/19 = 37%
Control
 21/38 = 55%
PE
10/24 = 42%
PE
CN, cast nephropathy; PE, plasma exchange; sFLC, serum free light chains.
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demonstrated in two recent publications 
that deal with the kinetics of free-light 
chain removal with the use of chemo-
therapy and plasma exchange.6,7 We 
would contend that the 50% reduction in 
free-light chains noted by Leung et al.11 
marks those who responded to chemo-
therapy, as is suggested by the two recent 
publications and the recent RCT.6,7,10
Is it time to cast away plasma exchange 
forever as an ineﬀective method of improv-
ing renal and broader outcomes in patients 
with multiple myeloma? The answer is 
clearly no. As Leung et al.11 highlight, the 
jury is still out, and there is no debate that 
better RCTs are needed to clarify the role 
of this therapy in multiple myeloma. How-
ever, is the American Society for Apher-
esis correct to describe plasma exchange 
as “having suggestion of beneﬁt for which 
existing evidence is insuﬃcient to estab-
lish the eﬃcacy of beneﬁt”? Our position 
is that the answer at this time is a clear yes. 
Our emphasis as a community should be 
to encourage patients to participate in 
future trials. There is a current RCT in the 
United Kingdom led by Dr. Gill Gaskin 
that commenced in 2004 and intends to 
enroll 280 patients with newly diagnosed 
multiple myeloma and acute kidney fail-
ure. Free-light chain measurement will be 
included, but renal biopsy is not an inclu-
sion criterion in this well-constructed trial. 
We await this larger study with anticipa-
tion, but in view of the concerns of Leung 
et al.11 about the need for renal biopsy, we 
would strongly encourage Leung et al. and 
those of similar interests to use both renal 
biopsy and serum free-light chain meas-
urements in constructing the randomized 
control study that will test their hypothesis 
that plasma exchange improves renal out-
comes in myeloma cast nephropathy. In 
the present environment it may be easier 
to recruit the numbers needed to carry 
out an RCT, as there will be less of the 
oﬀ-label use of plasma exchange that was 
noted in the previous RCT.10 The RCT by 
Clark et al.10 did suﬀer from the absence 
of renal biopsy and the measurement of 
serum free-light chain levels. However, 
we should not forget that the response rate 
with biopsy-proven cast nephropathy and 
measurement of free-light chains resulted 
in a similar 50% improvement in renal 
outcome for the cast nephropathy group of 
Leung et al.11 and the control and plasma 
exchange arms of the Clark et al. RCT.10
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